Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22996251 | 1.00 | KMT2A (0.48) | KMT2ALMNAHTTPIK3CDALDH1A1 | |
| SCHEMBL13850080 | 0.98 | KMT2A (0.46) | KMT2ALMNAHTTPIK3CDALDH1A1 | |
| SCHEMBL10232756 | 0.94 | KMT2A (0.53) | KMT2ALMNAHTTPIK3CDALDH1A1 | |
| SCHEMBL20363771 | 0.82 | PIK3CD (0.48) | KMT2APIK3CDHTR7MEN1MAPT | |
| SCHEMBL12958917 | 0.82 | ALDH1A1 (0.56) | KMT2ALMNAHTTALDH1A1KDM4E | |
| SCHEMBL27220451 | 0.82 | ALDH1A1 (0.56) | KMT2ALMNAHTTALDH1A1KDM4E | |
| SCHEMBL8860543 | 0.82 | ALDH1A1 (0.56) | KMT2ALMNAHTTALDH1A1KDM4E | |
| SCHEMBL426429 | 0.82 | — | — | |
| SCHEMBL14258662 | 0.81 | PIK3CD (0.48) | KMT2ALMNAHTTPIK3CDMEN1 | |
| SCHEMBL378213 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105217-A1 | 3-((8-((1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-12-21 | — | — | EP | disclosed |
| US-20090075981-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075981-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | US | disclosed |
| US-7423049-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423049-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070060572-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060572-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075981-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | KMT2A 3956/4885LMNA 2007/4885HTT 3258/4885 |
| US-20070060572-A1 | Inhibitors of p38 | MAPK1, MAPK3, MAP3K1 | KMT2A 3956/4885LMNA 2007/4885HTT 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.